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OBJECTIVES The objective of this study was to compare the outcome of patients .60 years of age with
younger patients after the Ross procedure.
BACKGROUND Currently, the Ross procedure is performed predominantly in young patients. Main
arguments against the Ross procedure in the elderly are the complexity of the operation and
related risks. Experience with the Ross procedure in patients .60 years of age is scarce.
METHODS Between February 1990 and August 1998, the Ross procedure was performed in 27 patients
(15 men and 12 women) .60 years of age (mean 64.2 6 3.1 years, range 60.5 to 70.6; group
A) and in 84 patients (68 men, 12 women) ,60 years of age (mean 43.8 6 12.4 years, range
15.2 to 59.4; group B). Echocardiography was applied at a mean follow-up of 28.4 6 21.0 and
25.2 6 21.4 months, respectively, to determine hemodynamic variables (ejection fraction,
fractional shortening, stroke volume, cardiac output), cardiac dimensions and autograft and
homograft valve function.
RESULTS There was one early and one late (esophageal bleeding) death in group B; the mortality rate
was 0% in group A. One autograft was replaced because of a subvalvular aneurysm, and one
patient was lost to follow-up (group B). There were no significant differences in cardiac
dimensions, grade of insufficiencies across homografts and autografts and hemodynamic
variables, except for a higher pressure gradient across the homograft in group B (maximal
pressure gradient 11.3 6 5.6 vs. 7.7 6 4.6 mm Hg in group A). The median New York Heart
Association functional class was I in both groups.
CONCLUSIONS Our seven years of experiences (mean follow-up 28 months) indicate that the Ross procedure
may be performed in selected patients .60 years of age without increased risk for mortality
or complications in experienced centers. (J Am Coll Cardiol 2000;36:1173–7) © 2000 by the
American College of Cardiology
The first successful clinical application of the pulmonary
autograft for aortic valve replacement was performed by
Donald Ross in 1967 (1). Over the following two decades,
the Ross procedure was applied by only a few surgeons, first
because of its technical complexity and second because of
the development of simpler alternatives, such as mechanical
and biologic valve prostheses. More widespread acceptance
and use by the surgical community came in the late 1980s,
when the first long-term results were published by Matsuki
et al. (2) and Ross et al. (3).
In 1993, an international registry was established (4). At
present, more than 600 Ross procedures per year are
performed worldwide in more than 104 centers. The current
main indications for the Ross procedure are single valve
pathology, mechanical or bioprosthetic valve failure, endo-
carditis limited to the aortic root and athletes or young
adults in whom anticoagulation is contraindicated and
optimal hemodynamic measures are desired, as well as
patient age between 11 and 50 years (5,6). Absolute con-
traindications for aortic valve replacement with the pulmo-
nary autograft are advanced three-vessel coronary artery
disease (CAD), other extensive valve pathology requiring
replacement, severely depressed left ventricular (LV) func-
tion, multisystemic organ failure (e.g., pulmonary, renal,
hepatic), pulmonary valve pathology (congenital, acquired,
iatrogenic) and Marfan syndrome (5). There is controversy
with regard to the upper age limit (.60 years of age) (5).
A main argument against the Ross procedure in elderly
patients is the longer and more complex operation (“two
valve surgery”) compared with a simple aortic valve replace-
ment, and the surgery-related complications in these pa-
tients. Other authors argue that a decline in the elastic
integrity of the pulmonary valve beyond age 40 to 50 years
may provide an unsuitable substitute for aortic valve replace-
ment, with unacceptable long-term results in patients .50
years of age (5).
However, the Ross procedure has a number of desirable
qualities, and it therefore becomes an attractive alternative
to conventional aortic valve replacement with mechanical or
biologic prostheses, even in the elderly. These qualities
include autologous tissue with documented long-term via-
bility (7), optimal hemodynamic data, regeneration capacity
with a possible resistance to infection, lack of valve noise,
low valve failure and thus reintervention rate, freedom from
anticoagulation and anticoagulation-related hemorrhage
and a low incidence of thromboembolic complications.
Experience with the Ross procedure in patients .60 years
of age is scarce. In this report, we describe our experience in
replacing the diseased aortic valve with a pulmonary au-
tograft in 27 patients .60 years of age, as well as the results
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of an echocardiographic study assessing hemodynamic data
and valve function of autografts and homografts in our
elderly patients versus a patient cohort of 84 patients ,60
years of age.
METHODS
Patients. Between February 1990 and August 1998, 111
patients with aortic valve disease underwent aortic valve
replacement with a pulmonary autograft. In addition, cor-
onary artery bypass graft surgery was performed in six
patients (group A, n 5 2; group B, n 5 4). Twenty-seven
patients were .60 years of age at the time of the operation
(15 men, 12 women). The mean age of this group (group A)
was 64.2 6 3.1 years (range 60.5 to 70.6). The age of the
remaining 84 patients (group B: 71 men, 13 women) was
,60 years (mean age 43.8 6 12.4 years, range 15.2 to 59.4).
The mean follow-up period of all patients was 26 6 21.3
months (0.1 to 99.1). All patients were evaluated clinically
at regular intervals at our hospital. The results at latest
examination are presented. Patient characteristics and op-
erative data are depicted in Table 1.
Exclusion criteria for the Ross procedure were severe
calcification of the aortic root, reduced ejection fraction
,40%, more than two-vessel CAD and anatomic or struc-
tural defects of the pulmonary valve and, particularly in the
elderly, reduced general state.
Operative techniques. Three techniques were used for
implanting the autologous pulmonary valve: 1) total aortic
root replacement; 2) inclusion; and 3) the subcoronary
technique. The operative techniques are described in detail
elsewhere (8,9). Using the subcoronary technique, special
care was taken to match the size of the autograft to the
aortic root. A size difference up to 3 mm was accepted.
Otherwise, a reduction annuloplasty, according to David
(10), was performed, or the root at the sinotubular junction
was adjusted to the autograft diameter during closure of the
aortotomy that extended into the noncoronary sinus. All
patients were operated on under standard cardiopulmonary
bypass conditions with a membrane oxygenator (Hollow
Fiber Oxygenator, Spiral Gold, Baxter, Puerto Rico), at
moderate systemic hypothermia with cold crystalloid car-
dioplegia (St. Thomas’ Hospital solution) for myocardial
protection.
Echocardiographic data acquisition and measurements.
Informed, written consent was obtained before echocardi-
ography. The investigative procedures were in accordance
with institutional guidelines. Transthoracic echocardio-
grams were obtained on a Hewlett-Packard Sonos 2500
system with 2.5- and 1.9-MHz ultrasound transducers
during routine follow-up and recorded on VHS videotape.
A modified electrocardiographic (ECG) lead I was contin-
uously recorded. Blood pressure (BP) was measured by cuff
sphygmomanometry (Dinamap, Siemens, Erlangen, Ger-
many).
Two-dimensional echocardiography. The morphology of
the aortic cusps was examined, and measurements of stan-
dard dimensions were made in standard longitudinal and
Abbreviations and Acronyms
AR 5 aortic regurgitation
BP 5 blood pressure
CAD 5 coronary artery disease
ECG 5 electrocardiographic
LV 5 left ventricular, left ventricle
Table 1. Preoperative Clinical and Operative Data
Group A
(>60 years old)
(n 5 27)
Group B
(<60 Years Old)
(n 5 80)
p
Value
Age at operation (yrs) 64.2 6 3.1 43.8 6 12.4 , 0.001
Age at examination (yrs) 66.5 6 3.7 45.9 6 12.4 , 0.001
Follow-up (months) 28.4 6 21 25.2 6 21.4 NS
Male/female ratio 15:12 68:12
LVEF (laevocardiogram) 69 6 9.8 68 6 10.3 NS
NYHA functional class
I 0 6 NS
II 11 21 NS
II/III 4 21 NS
III 4 14 NS
III/IV 4 7 NS
IV 0 1 NS
BSA (m2) 1.9 6 0.2 2.1 6 0.6 NS
AI1AS 16 49
AS 5 8
AI 6 23
Bypass time (min) 202 6 38.5 203 6 29.4 NS
Ischemic time (min) 145 6 29.3 148 6 24.6 NS
Data are presented as the mean value 6 SD or number of patients.
AI 5 aortic (valve) insufficiency; AI1AS 5 combined aortic valve disease; AS 5 aortic (valve) stenosis; BSA 5 body surface
area; LVEF 5 left ventricular ejection fraction; NS 5 not significant; NYHA 5 New York Heart Association.
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cross-sectional views. Left ventricular end-systolic and end-
diastolic volumes were obtained from apical two- and
four-chamber views. Diastole was defined as the beginning
of the QRS complex on the simultaneous ECG recording.
Continuous wave, pulsed and color flow Doppler images.
Maximal velocities across the aortic and pulmonary valve
were obtained by using a continuous wave Doppler imaging
transducer. To obtain the highest velocity across the aortic
valve, the independent (Pedoff) 1.9-MHz nonimaging
transducer was also used. The maximal pressure gradient
was calculated using the modified Bernoulli equation.
To assess aortic regurgitation (AR), pulsed wave Doppler
and color flow Doppler were used for mapping the LV
outflow tract, and continuous spectral Doppler was applied
to measure the deceleration slope and pressure half-time of
the aortic regurgitant jet. Furthermore, AR was quantitated
by measuring the jet height at the valve orifice and com-
paring it with the height of the LV outflow tract according
to the method of Perry et al. (11): ratio of 1% to 24% 5
grade I; 25% to 46% 5 grade II; 47% to 64% 5 grade III;
and $65% 5 grade IV. For assessment of pulmonary
regurgitation, pulsed wave, continuous wave and color
Doppler were performed. Semiquantitative assessment of its
severity was based on the length and width of the regurgi-
tant jet and the distance it reaches into the right ventricular
outflow tract on the parasternal short-axis view.
Statistical analysis. Categoric data are given as total num-
bers and relative frequencies, and continuous data as the
mean value 6 SD, unless otherwise stated. Different groups
were compared using the t test or the Mann-Whitney U
test. For correlation analysis, the Spearman rank correlation
coefficient was calculated. A p value , 0.05 was considered
to indicate statistical significance. All tests were two-sided.
Regression analysis was carried out for each variable so that
any effect of variable length of follow-up time was factored
in when comparing the two age groups; the results obtained
were similar to the unadjusted results shown in Table 2.
Statistics were performed using statistical software (SPSS
for Windows 8.0, SPSS Inc.).
RESULTS
Clinical outcome. The mortality rate in group A was 0%.
Two patients had thromboembolic events: one patient (67
years of age) had a stroke, with a known atrial thrombus six
months after the operation, with almost full recovery; and
one patient 69 years of age had a transient ischemic attack
10 days after the operation.
In group B, one patient died 10 days after the operation
(hospital mortality rate ,1%), and one patient died 18
months after the operation because of esophageal bleeding.
In another patient, replacement of the free-standing au-
tograft with a mechanical aortic valve prosthesis was neces-
sary due to an aortic subvalvular aneurysm six years after
root replacement. No thromboembolic events occurred in
the patients in group B. One patient was lost to follow-up.
Thus, group B comprises 80 patients at echocardiographic
follow-up. The median of New York Heart Association
functional class was I in both groups.
Hemodynamic data and valve function. Postoperative
hemodynamic data are depicted in Table 2. Heart rate,
stroke volume, cardiac output, ejection fraction and LV
dimensions were comparable between the groups; only the
systolic BP was significantly higher in the elderly. Also, the
maximal pressure gradient across the homograft was signif-
icantly higher in group B (11.3 6 5.6 mm Hg) than in
group A (7.7 6 4.6 mm Hg; p 5 0.004). There was a weak
but significant correlation (p , 0.001) between the duration
of follow-up and the pressure gradient across the homograft
in group B (r 5 0.391) (Fig. 1), but not in group A (r 5
0.274, p 5 0.176) (Fig. 1).
DISCUSSION
This study serves to further clarify the role of the Ross
procedure in the surgical treatment of the diseased aortic
valve. In particular, the age limit is addressed. We did not
find any difference in clinical outcome and hemodynamic
results when comparing elderly patients between 60 and 70
Table 2. Clinical and Hemodynamic Outcomes and
Valve Function
Group A
(n 5 27)
Group B
(n 5 80)
p
Value
NYHA functional class
(median)
I I NS
SBP (mm Hg) 150 6 20 133 6 19 ,0.001
DBP (mm Hg) 79 6 14 81 6 13 NS
LVESD (mm) 32.8 6 6.6 35.2 6 7.9 NS
LVEDD (mm) 49.8 6 5.9 50.7 6 7.5 NS
HR (beats/min) 69 6 14 72 6 14 NS
SV(ml) 66.8 6 22.6 73.6 6 27.6 NS
CO (liters/min) 6.3 6 1.9 6.5 6 1.9 NS
LVEF (%) 64 6 9.8 61 6 9.8 NS
FS (%) 33.9 6 9.0 31.2 6 8.6 NS
AV-PG max (mm Hg) 6.6 6 3.2 6.1 6 2.7 NS
AV-PG mean (mm Hg) 3.2 6 1.7 3.7 6 1.6 NS
AR grade
0 15 56 NS
I 11 22 NS
II 1 2 NS
PV-PG max (mm Hg) 7.7 6 4.6 11.3 6 5.6 0.004
PV-PG mean (mm Hg) 4.3 6 2.5 6.5 6 3.2 0.002
PI grade
0 15 56 NS
I 12 22 NS
II 0 2 NS
Data are presented as the mean value 6 SD, except for NYHA functional class, or the
number of patients.
AR 5 aortic valve regurgitation; AV-PG max and mean 5 instantaneous and
mean, respectively, pressure gradient across the aortic valve; CO 5 cardiac output;
DBP 5 diastolic blood pressure; FS 5 fractional shortening; HR 5 heart rate;
LVEDD 5 left ventricular end-diastolic diameter; LVEF 5 left ventricular ejection
fraction; LVESD 5 left ventricular end-systolic diameter; NS 5 not significant;
NYHA 5 New York Heart Association; PI 5 pulmonary valve insufficiency; PV-PG
max and mean 5 instantaneous and mean, respectively, pressure gradient across the
pulmonary valve; SBP 5 systolic blood pressure; SV 5 stroke volume.
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years of age with younger patients, except for a significantly
lower pressure gradient across the homograft in the elderly.
Choice of valve substitute in elderly patients. The Ross
procedure is generally accepted for patients ,50 years of
age. The choice of a prosthesis for aortic valve replacement,
particularly for patients between 60 and 70 years of age,
remains controversial. It is determined, among other factors,
by the intrinsic characteristics of the replacement device and
the patient group to be operated on, as well as by the
experience of the surgical team. Mechanical valves that offer
extended durability have the constant risk of valve-related
complications (12,13). In many cardiac surgical centers, the
mechanical valve is not the valve of choice for elderly
patients; instead it is a bioprosthesis, whether stented or
stentless. The advantages of bioprostheses include a lower
incidence of thromboembolism and valve thrombosis and
the relative freedom from the risk of anticoagulant-related
hemorrhage. A bioprosthesis is reported to be prone to
reduced degeneration and structural valve failure in older
patients. Cohen et al. (14) demonstrated that at 12 years,
the freedom from primary tissue failure was lower in
patients ,65 years of age than in those $65 years of age.
Burr et al. (15) reported freedom from structural valve
deterioration of a bioprosthesis in aortic position of 94.9 6
1.8% at 10 years for patients 65 to 69 years old (15).
Valve reoperation. Nevertheless, there is a considerable
risk that the valve will require re-replacement if a biopros-
thesis is used in patients between 60 and 70 years of age.
Especially after 12 years postoperatively, the freedom from
valve degeneration decreases exponentially (15). Conse-
quently, most patients will need reoperation at an advanced
age, between 75 and 80 years. At such an age, the indication
for reoperation is restricted, and the risk that an operation
will be needed is increased. It is reported to be as high as
14% to 25% in patients .70 years of age (16). In many
reports, valve failure indicates replacement of the biopros-
thesis. However, not only the reoperation, but also the valve
degeneration that produces a hemodynamic burden on the
LV, without fulfilling the criteria for reoperation, may have
some influence on ventricular function and probably the
longevity of the patient. Therefore, it is desirable that these
elderly patients receive a valve substitute with a reduced rate
of degeneration in order to prevent reoperation and func-
tional impairment. In addition, older patients hope to be
operated on only once and to be free of complications and
anticoagulation. Furthermore, socially integrating these pa-
tients as much as possible, so they are active and productive
persons, reduces the time span of senescence. These factors,
taken together, suggest that there is a meaningful rationale
for older patients to receive the Ross procedure. However,
patients must be selected for their level of activity and
general status, social situation, life expectancy and comor-
bidity to outweigh the risks versus the benefits of this special
surgical procedure in comparison with the excellent results
of bioprostheses. Reported freedom from reoperation after
the Ross procedure at 20 years was 75% for the autograft
and 80% for the homograft (17). Only one of our patients
had to be reoperated on because of a subvalvular aneurysm;
the leaflets were macroscopically intact. These data are
superior to those for bioprostheses and most likely can be
projected into the advanced-age group.
Autograft function. We did not find significant autograft
dysfunction in group A. Whether this reduced rate of
degeneration of the autograft will stand the test of time
remains to be established. The longest follow-up time in
group A was 83.1 months, and in this patient, there was no
significant insufficiency and no pressure gradient, suggesting
excellent hemodynamic data. Most patients had no, or mild,
aortic insufficiency, with no difference between the groups.
The high incidence of no AR is probably related to the exact
size matching at the base and sinotubular junction. In
conjunction with the low pressure gradients, these hemo-
dynamic data may beneficially influence the long-term
function of the LV and probably patient survival as well.
Homograft function. It is interesting that we found a
significantly lower pressure gradient across the homograft in
group A. Whether this is related to a reduced immunologic
response with increasing age and a resulting lower degree of
shrinkage of the homograft as a source for development of
a pressure gradient remains to be determined. Vogt et al.
(18) reported an attenuated immunologic reaction of the
allografts in elderly patients compared with children. Fur-
thermore, there was no authentic correlation between the
duration of follow-up and the pressure gradient across the
homograft in the elderly. In the younger patients, this
correlation was weak but significant, indicating that in this
age group there is a tendency for a time-related increase in
the pressure gradient across the homograft. Therefore, close
follow-up, especially in the younger patients, is desirable.
Serial longer term follow-up studies are necessary to clarify
this item. In this regard, Moidl et al. (19) reported an
increase in flow velocities across the homograft up to one
year after the operation, suggesting a dynamic graft-related
Figure 1. Individual values of maximal (max) pressure gradients across the
pulmonary valve (PV-PG) in relation to the follow-up interval (group A:
r 5 0.274, p 5 0.176; group B: r 5 0.391, p , 0.001). Group A 5 patients
$60 years of age; group B 5 patients ,60 years of age.
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process. It must be considered, however, that in our series
the maximal pressure gradient across the homograft did not
exceed 22 mm Hg, even after a maximal follow-up period of
eight years, indicating that the assumed valve-related ste-
notic process is probably of minor significance in the
majority of patients.
Operative risk. In group A, we could not find an increased
operative risk. There was no evidence that the longer
ischemic time of the myocardium had an impact on the
myocardial function of either group A or group B. Normal
values were found for LV ejection fraction, cardiac output
and LV dimensions in both groups after the operation.
Whether this holds true for patients with more reduced
preoperative LV function remains questionable. For these
patients, bioprostheses or mechanical valves are probably the
better surgical procedure.
Thromboembolic events. Two thromboembolic events
occurred in group A. In the first patient, the thromboem-
bolic event may be caused by an atrial thrombus that was
detected postoperatively. In the other patient, the transient
ischemic attack can be attributed to the pledgets that we
used for fixation of the commissures in the first patients or
to the atherosclerotic aging process. The exact source of
embolism is difficult to define, especially in the advanced age
group. Prencipe et al. (20) reported a prevalence of stroke of
7.3% in patients .65 years of age without heart disease.
Conclusions. The Ross procedure provides excellent re-
sults in elderly selected patients up to 70 years of age, in
terms of clinical status, hemodynamic data and semilunar
valve function. The pressure gradient across the homograft
was significantly lower in the older age group. Longer
follow-up periods with larger numbers of patients are
necessary for final judgment of this extended indication with
the Ross procedure, particularly if these valve-related ad-
vantages have beneficial effects on patient survival.
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